**Supplementary Table.** Efficacy endpoints at Week 52. Intent to treat, non-responder imputation analysis. CDAI, Crohn’s Disease Activity Index.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Placebo(n = 113)** | **GED-0301 160 mg/40 mg, 4-Week Alternating(n = 120)** | **GED-0301 160 mg/40 mg(n = 128)** | **GED-0301 160 mg/160 mg, 4-Week Alternating(n = 117)** | **GED-0301 Total(n = 365)** |
| Clinical remission (CDAI score <150), % | 5.3 | 2.5 | 9.4 | 3.4 | 5.2 |
| Clinical response (decrease from baseline ≥100), % | 6.2 | 5.0 | 10.2 | 6.0 | 7.1 |
| Endoscopic response-50, % | 3.5 | 0.8 | 1.6 | 1.7 | 1.4 |

**Supplementary Figure.** Proportion of patients achieving clinical remission, defined as a CDAI score of <150, at Week 12 by subgroup (intent-to-treat population, non-responder imputation).

